Proactive Research analyst Emma Ulker says the news this morning that Open Orphan PLC (LON:ORPH) subsidiary hVIVO has signed a £4mln contract with an unnamed top-three global pharma company is evidence that the validation is building as well as recognition amongst larger players in the industry. The respiratory syncytial virus (RSV) trial will take place at hVIVO’s London quarantine unit and is expected to be completed by the end of the first quarter next year.
viewOpen Orphan PLC
Open Orphan: New deal with top-three pharma company is 'evidence validation is building'
Quick facts: Open Orphan PLC
Price: 28.9 GBX
AIM:ORPH
Market: AIM
Market Cap: £190.85 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Health
Emyria appoints global pharmaceutical expert to chair Strategic Advisory Board
4 days, 6 hours ago
Mining
Chalice Mining bolsters board with appointment of highly regarded former Rio...
4 days, 8 hours ago
